234 completed, 31 terminated, 27 unknown, 14 active not recruiting. 183 Phase 2, 116 Phase 1, 42 Phase 3, 4 Not applicable, 3 Early Phase 1.
Follow Irinotecan Hydrochloride: new trials by email Literature Review of Irinotecan Hydrochloride trials Research Report on Irinotecan Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Rhabdomyosarcoma | Phase 3 | Recruiting | Children's Oncology Group | 342 | 2026-07-14 | 2026-08-25 |
| A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure BL-M07D1, Oxaliplatin, Calcium levofolinate - Biliary Tract Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 398 | 2026-07-07 | 2026-07-24 |
| A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) BL-B01D1, Oxaliplatin, Calcium levofolinate - Biliary Tract Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 538 | 2026-06-29 | 2026-07-24 |
| A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment BL-M05D1, Paclitaxel, Docetaxel - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 438 | 2026-05-15 | 2026-07-08 |
| Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma | Phase 2 / Phase 3 | Terminated | Children's Oncology Group | 2 | 2025-11-10 | 2026-10-05 |
| Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma rhIL-15, Dinituximab, Temozolomide - Neuroblastoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 40 | 2025-10-21 | 2026-10-21 |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 356 | 2025-08-21 | 2026-08-25 |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer Amivantamab, Cetuximab, 5-fluorouracil - Colorectal Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 1000 | 2024-10-18 | 2026-09-25 |
| Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer Tislelizumab, Oxaliplatin, Levo-Leucovorin - Gastric Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 36 | 2024-01-01 | 2024-01-09 |
| Combination Therapy in Cancers With Mutations in DNA Repair Genes Niraparib, Irinotecan - Metastatic Solid Tumor, BRCA1 Mutation | Phase 1 | Recruiting | University of California, San Francisco | 24 | 2023-05-23 | 2026-06-18 |
| Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer Tislelizumab, Irinotecan Hydrochloride, cetuximab - Colorectal Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 23 | 2023-04-05 | 2023-04-05 |
| Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer Gemcitabine Hydrochloride, Nab-paclitaxel, Fluorouracil - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Flemming Forsberg | 120 | 2021-12-06 | 2025-11-04 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-10-20 | 2026-09-10 |
| Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma Fine-Needle Aspiration, Irinotecan, Irinotecan Hydrochloride - Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-09-15 | 2022-02-10 | |
| Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride - Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | Phase 3 | Active not recruiting | Erasmus Medical Center | 378 | 2021-09-07 | 2026-05-15 |
| Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 10 | 2021-08-13 | 2026-08-21 |
| NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer Capecitabine, Fluorouracil, Irinotecan Hydrochloride - Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8 | Phase 2 | Active not recruiting | OHSU Knight Cancer Institute | 42 | 2021-05-27 | 2026-01-14 |
| Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium - Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 358 | 2020-10-13 | 2026-09-04 |
| Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies Sym021, Sym022, Sym023 - Metastatic Cancer, Solid Tumor | Phase 1 | Completed | Symphogen A/S | 78 | 2020-10-12 | 2024-06-26 |
Showing 20 of 329. Sign in to see all of them.
Colorectal Neoplasms (98) · Rectal Neoplasms (97) · Colonic Neoplasms (96) · Stomach Neoplasms (30) · Pancreatic Neoplasms (27) · Lung Neoplasms (25) · Esophageal Neoplasms (24) · Central Nervous System Neoplasms (20) · Neoplasm Metastasis (20) · Adenocarcinoma Of Esophagus (19) · Brain Neoplasms (16) · Glioblastoma (15) · Astrocytoma (14) · Carcinoma, Non-Small-Cell Lung (14) · Gliosarcoma (14)
National Cancer Institute (NCI) (52) · Alliance for Clinical Trials in Oncology (26) · Memorial Sloan Kettering Cancer Center (20) · Children's Oncology Group (13) · SWOG Cancer Research Network (11) · Roswell Park Cancer Institute (10) · City of Hope Medical Center (9) · Federation Francophone de Cancerologie Digestive (8) · Eastern Cooperative Oncology Group (6) · GERCOR - Multidisciplinary Oncology Cooperative Group (6) · Jonsson Comprehensive Cancer Center (6) · Case Comprehensive Cancer Center (5) · M.D. Anderson Cancer Center (5) · University of Chicago (5) · Duke University (4)
United States (252) · Canada (38) · France (30) · Puerto Rico (15) · Australia (13) · United Kingdom (13) · Italy (11) · Japan (9) · Switzerland (9) · New Zealand (8) · Belgium (7) · Germany (7) · Spain (7) · Netherlands (6) · China (5)
David H. Ilson, MD, PhD (9) · Charles R. Thomas, MD (3) · Heinz-Josef Lenz, MD (3) · Henry S. Friedman, MD (3) · John R. Murren, MD (3) · Leonard B. Saltz, MD (3) · Marc Ychou, MD, PhD (3) · Nancy E. Kemeny, MD (3) · Neal J. Meropol, MD (3) · Al B. Benson, MD, FACP (2) · Alfredo Falcone, MD (2) · Athanassios Argiris, MD (2) · Claus-Henning Koehne, MD (2) · Corey J. Langer, MD (2) · Cynthia S. Kretschmar, MD (2)
PMID 31268130, PMID 38603649, PMID 12196376, PMID 12393999, PMID 12794246, PMID 12794247, PMID 12885811, PMID 12963697, PMID 14630685, PMID 14769136, PMID 14769140, PMID 14998842, PMID 15565574, PMID 15641483, PMID 15939923, PMID 16062075, PMID 16096702, PMID 16200343, PMID 16399443, PMID 16446336, PMID 16533878, PMID 16601427, PMID 16648503, PMID 16777690, PMID 16863926, PMID 16873427, PMID 17026790, PMID 17065590, PMID 17216531, PMID 17264331, PMID 17317837, PMID 17410043, PMID 17426973, PMID 17429623, PMID 17510208, PMID 17545848, PMID 17553200, PMID 17630037, PMID 17785765, PMID 17989978, PMID 18056194, PMID 18065406, PMID 18182667, PMID 18414865, PMID 18417462, PMID 18484593, PMID 18501081, PMID 18594219, PMID 18661102, PMID 18676757
U10CA031946 (9), U10CA180886 (9), U10CA032102 (8), U10CA098543 (8), P30CA008748 (5), P30CA033572 (5), U10CA180888 (5), P30CA015083 (4), P30CA043703 (4), U10CA021115 (4), P30CA006927 (3), P30CA006973 (3), P30CA014599 (3), P30CA016672 (3), U01CA062502 (3)